Your browser doesn't support javascript.
loading
Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche.
Baldominos, Pilar; Barbera-Mourelle, Alex; Barreiro, Olga; Huang, Yu; Wight, Andrew; Cho, Jae-Won; Zhao, Xi; Estivill, Guillem; Adam, Isam; Sanchez, Xavier; McCarthy, Shannon; Schaller, Julien; Khan, Zara; Ruzo, Albert; Pastorello, Ricardo; Richardson, Edward T; Dillon, Deborah; Montero-Llopis, Paula; Barroso-Sousa, Romualdo; Forman, Juliet; Shukla, Sachet A; Tolaney, Sara M; Mittendorf, Elizabeth A; von Andrian, Ulrich H; Wucherpfennig, Kai W; Hemberg, Martin; Agudo, Judith.
Afiliación
  • Baldominos P; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Barbera-Mourelle A; Center for Cancer Research at Mass General Hospital, Boston, MA 02114, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Barreiro O; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA; Center for Immune Imaging, Harvard Medical School, Boston, MA 02215, USA.
  • Huang Y; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA.
  • Wight A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA.
  • Cho JW; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Zhao X; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Estivill G; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Adam I; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Sanchez X; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA.
  • McCarthy S; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard T.H. Chan School of Public Health, Biological Sciences in Public Health PhD Program, Boston, MA 02215, USA.
  • Schaller J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Khan Z; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Ruzo A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Pastorello R; Division of Breast Surgery, Brigham and Women's Hospital, Boston, MA 02215, USA; Breast Oncology, Dana-Farber Brigham Cancer Center, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
  • Richardson ET; Harvard Medical School, Boston, MA 02215, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Dillon D; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Montero-Llopis P; MicRoN Core, Harvard Medical School, Boston, MA 02215, USA.
  • Barroso-Sousa R; Oncology Center, Hospital Sírio-Libanês, 70200-730 Brasília, Brazil.
  • Forman J; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Shukla SA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Mittendorf EA; Division of Breast Surgery, Brigham and Women's Hospital, Boston, MA 02215, USA; Breast Oncology, Dana-Farber Brigham Cancer Center, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA.
  • von Andrian UH; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA; Center for Immune Imaging, Harvard Medical School, Boston, MA 02215, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
  • Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA; Ludwig Center at Harvard, Boston, MA 02215, USA.
  • Hemberg M; Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Agudo J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Immunology, Harvard Medical School, Boston, MA 02215, USA; Ludwig Center at Harvard, Boston, MA 02215, USA. Electronic address: judith_agudo@dfci.harvard.edu.
Cell ; 185(10): 1694-1708.e19, 2022 05 12.
Article en En | MEDLINE | ID: mdl-35447074
ABSTRACT
Immunotherapy is a promising treatment for triple-negative breast cancer (TNBC), but patients relapse, highlighting the need to understand the mechanisms of resistance. We discovered that in primary breast cancer, tumor cells that resist T cell attack are quiescent. Quiescent cancer cells (QCCs) form clusters with reduced immune infiltration. They also display superior tumorigenic capacity and higher expression of chemotherapy resistance and stemness genes. We adapted single-cell RNA-sequencing with precise spatial resolution to profile infiltrating cells inside and outside the QCC niche. This transcriptomic analysis revealed hypoxia-induced programs and identified more exhausted T cells, tumor-protective fibroblasts, and dysfunctional dendritic cells inside clusters of QCCs. This uncovered differential phenotypes in infiltrating cells based on their intra-tumor location. Thus, QCCs constitute immunotherapy-resistant reservoirs by orchestrating a local hypoxic immune-suppressive milieu that blocks T cell function. Eliminating QCCs holds the promise to counteract immunotherapy resistance and prevent disease recurrence in TNBC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas Límite: Humans Idioma: En Revista: Cell Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Triple Negativas Límite: Humans Idioma: En Revista: Cell Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos